Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCING: IL13Ra2 CAR-T in r/r WHO4 glioma
NCT06355908Phase 1Suspended
- Start
- Mar 2024
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KLG3BBz-huC825 in glioma. Primary endpoint: Safety of IL13Rα2 CAR-T at Day 730. Started Mar 2024; status: suspended.
02
Drugs
KLG3BBz-huC825
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06355908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355908.